Skip to main content
logo
Pelthos Therapeutics Inc. (PTHS)
NYSEAMERICAN: PTHS · Real-Time Price · USD
27.93
-1.02 (-3.52%)
Aug 14, 2026, 1:00 PM EDT - Market open

Pelthos Therapeutics Financials Overview

Millions USD. Fiscal year is Jan - Dec.

Revenue & Profits
Chart
Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Revenue
43.316.8----
Revenue Growth
------
Gross Profit
32.8111.58-1.18--0.39-0.21
Operating Income
-56.75-31.41-7.57-6.86-2.32-0.84
Net Income
-86.39-43.32-7.96-7.38-2.46-0.6
Earnings Per Share
-26.36-23.04-14.27-57.82-56.48-
EPS Growth
------

Revenue by Segment
Chart
Fiscal YearFY 2025
Period EndingDec '25
Commercial Operations
16.21
Research and Development Operations
0.59
Total
16.8

Cash & Debt
Chart
Fiscal YearCurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Cash & Investments
24.1917.970.510.10.060
Total Debt
-34.832.191.270.541.1
Net Cash (Debt)
24.19-16.86-1.67-1.17-0.49-1.1
Net Cash Growth
------
Net Cash Per Share
7.38-8.96-3.00-9.18-11.15-

Cash Flow & CapEx
Chart
Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Operating Cash Flow
--22.59-5.79-0.98-1.57-1.59
Capital Expenditures
--0.1----
Free Cash Flow
--22.69-5.79-0.98-1.57-1.59
Free Cash Flow Growth
------

Margins
Chart
Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Gross Margin
75.75%68.94%----
Operating Margin
-131.06%-187.01%----
Pretax Margin
-216.56%-301.91%----
Profit Margin
-199.50%-257.93%----
FCF Margin
--135.09%----

Valuation
Chart
Fiscal YearCurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingAug '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
PS Ratio
2.325.70----